[Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma]

The incidence and mortality of HCC in China account for approximately 50% of all cases worldwide. Low early diagnosis rate and high postoperative recurrence rate are two major causes for poor 5-year survival rate of HCC patients in China. At present, multiple problems such as low performance and compliance of screening technology and lack of effective markers for predicting postoperative recurrence, remain to be resolved. Due to the simplicity and accuracy, new molecular markers, such as liquid biopsy, are expected to serve as supplementary tools to traditional screening and early warning approaches, thereby realizing early detection and accurate treatment of HCC. In this article, research progress upon the clinical application of liquid biopsy in early screening and prediction of postoperative recurrence of HCC was reviewed, and prospects the future research.中国肝细胞癌（HCC）发病及死亡人数约占全球50%。HCC早期诊断率低及术后复发率高是我国HCC患者5年生存率欠佳的两大原因。当前存在筛查技术性能及依从性较低、缺乏有效预测术后复发标志物等问题。液体活检等新型分子标志物因其简便、精准等特点，有望成为传统筛查预警方法的有益补充，实现HCC的早期发现及精准治疗。现就液体活检在HCC早筛及治疗后复发预测中的临床转化应用进行论述，并对未来研究进行展望。.